TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6750118
Drug: Indomethacin capsules
Normalized name: Indomethacin Capsules
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin capsules (50 mg for the first 5 days, 100 mg for the second 5 days)
Study: 6750118
Drug: Indomethacin suppositories
Normalized name: Indomethacin Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppositories (50 mg for the first 5 days, 100 mg for the second 5 days)
Study: 27654816
Drug: Dexmedetomidine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine as a primary sedative (n = 138; 11%)
Study: 27654816
Drug: Dexmedetomidine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine as a secondary sedative (n = 280; 23%)
Study: 27654816
Drug: Dexmedetomidine as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine as a periextubation agent (n = 178; 15%)
Study: 18990967
Drug: Tiotropium 8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 8, 16, or 32 microg administered once daily via Respimat SMI for 14 days
Study: 18990967
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in both studies
Study: 1464208
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg hyoscine-N-butylbromide
Study: 1464208
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg hyoscine-N-butylbromide
Study: 1464208
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg hyoscine-N-butylbromide
Study: 31551219
Drug: Oxycodone (O)
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone (O) alone postoperatively
Study: 31551219
Drug: Dexmedetomidine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine combined with oxycodone (DO) postoperatively
Study: 20205269
Drug: Optimal weighted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal weighted combination of pseudo-likelihood estimators
Study: 18609291
Drug: Hydration scheme
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration scheme of 290 ml of water/m2
Study: 18609291
Drug: Hydration scheme
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration scheme of 580 ml of water/m2
Study: 11858378
Drug: Gemfibrozil (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (administered to 7 patients for 4 months)
Study: 11858378
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered to 5 patients for 4 months)
Study: 10360847
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) - additional 20 mg oral morphine (10 mg at 12-h intervals)
Study: 10360847
Drug: Dipyrone Group
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone Group (DG) - 500 mg oral dipyrone at 6-h intervals
Study: 10360847
Drug: Nitroglycerin Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin Group (NG) - 5 mg nitroglycerin patch daily
Study: 10360847
Drug: Ketamine Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine Group (KG) - 0.5 mg/kg oral ketamine at 12-h intervals
Study: 8839554
Drug: Omeprazole, 20
Normalized name: Omeprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, 20 mg once a day
Study: 8839554
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 tablet twice a day
Study: 8839554
Drug: Misoprostol, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol, 400 micrograms twice a day
Study: 6389394
Drug: Antimicrobial agents
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial agents (antibiotics)
Study: 1971320
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mifepristone, given orally 48 h before surgery
Study: 25150401
Drug: AA attendance
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AA attendance during treatment (12 weeks of outpatient treatment)
Study: 21676165
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (12.5 mg diphenhydramine)
Study: 19112061
Drug: Plain articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain articaine 50 mg
Study: 19112061
Drug: Plain prilocaine
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plain prilocaine 50 mg
Study: 16680610
Drug: ROB‐ML (robotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: ROB‐ML (robotics and motor learning)
Study: 16680610
Drug: FNS‐ML (functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNS‐ML (functional neuromuscular stimulation and motor learning)
Study: 9814448
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (methylprednisolone, 1 g i.v. for 2 consecutive days a week for 6 weeks)
Study: 7657044
Drug: alpha‐interferon (IFN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐interferon (IFN) alfa‐2b (6 MU 3 times weekly for the first month and 3 MU for the next 11 months)
Study: 27942999
Drug: Algorithm-based treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm-based treatments (AT)
Study: 15514382
Drug: Cancer consultation
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer consultation preparation package (CCPP)
Study: 9393429
Drug: Increased awareness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased awareness of tobacco use as a risk factor for osseointegration of dental implants
Study: 8481628
Drug: Allopurinol (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (test preparation)
Study: 24814528
Drug: pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 30 mg/day
Study: 22747647
Drug: Diflunisal administration
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal administration
Study: 20727660
Drug: Anti-psychotic medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-psychotic medication
Study: 18850554
Drug: Nonpenetrating deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpenetrating deep sclerectomy (NPDS) with reticulated hyaluronic acid (SK-GEL) scleral implant
Study: 18850554
Drug: Both NPDS
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both NPDS and PT (with Mitomycin C 0.2 mg/mL applied intraoperatively)
Study: 1980278
Drug: Bisoprolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (20 mg QD)
Study: 7461879
Drug: Short-term alcohol
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term alcohol treatment intervention
Study: 23565581
Drug: Combination duloxetine-methadone
Normalized name: methadone, combinations excl. psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination duloxetine-methadone
Study: 19586568
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg lutein/d (Group L6)
Study: 19586568
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg lutein/d (Group L12)
Study: 9645459
Drug: Intrahepatic arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrahepatic arterial infusion of 131I-radiolabelled anti-HCC monoclonal antibody (Hepama-1 mAb)
Study: 9645459
Drug: Intrahepatic-arterial chemotherapy
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrahepatic-arterial chemotherapy (non-RIT group)
Study: 8194689
Drug: CCK-33 infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK-33 infusion
Study: 18333862
Drug: Maraviroc (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc (300 mg b.i.d.)
Study: 9771399
Drug: Atropine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (15 micrograms/kg bolus intravenously, 4 micrograms/kg/h infusion)
Study: 2891886
Drug: Acyclovir or
Normalized name: acyclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir or vidarabine treatment for HSV-1 encephalitis
Study: 2891886
Drug: Acyclovir or
Normalized name: acyclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir or vidarabine treatment for HSV-2 encephalitis
Study: 26628527
Drug: IVIG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG plus cyclosporin A (CsA) (5 mg/kg/day for 5 days; Neoral) plus high-dose IVIG (2 g/kg for 24 h and aspirin 30 mg/kg/day)
Study: 26628527
Drug: High-dose IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IVIG alone (2 g/kg for 24 h and aspirin 30 mg/kg/day)
Study: 23800403
Drug: Esomeprazole 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 0.5 mg/kg once daily for up to 14 days
Study: 21968669
Drug: rosacea treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosacea treatment system (RTS)
Study: 21968669
Drug: metronidazole 0.75%
Normalized name: METRONIDAZOLE 0.75% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: metronidazole 0.75% gel plus standard skin care (M+SSC)
Study: 16163443
Drug: Triamcinolon acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolon acetonide 40 mg/ml plus lidocaine 2%
Study: 2951805
Drug: disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: disodium cromoglycate (DSCG) (10 mg)
Study: 26766141
Drug: mongersen 40
Normalized name: Mongersen
DrugBank: Mongersen (DB15019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mongersen 40 mg/day
Study: 26766141
Drug: mongersen 160
Normalized name: Mongersen
DrugBank: Mongersen (DB15019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mongersen 160 mg/day
Study: 26766141
Drug: mongersen 10
Normalized name: Mongersen
DrugBank: Mongersen (DB15019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mongersen 10 mg/day
Study: 26766141
Drug: mongersen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: mongersen (all doses)
Study: 22594467
Drug: Clonidine 3-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 3-4 μg kg(‐1) (C4)
Study: 22594467
Drug: Clonidine 7-8
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 7-8 μg kg(‐1) (C7)
Study: 19859698
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (0 mg)
Study: 19859698
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine (5 mg and 10 mg)
Study: 18022350
Drug: Lignocaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine (0.2 mL without vasoconstrictor)
Study: 18022350
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.2 mL)
Study: 11079810
Drug: 0.2 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 U/kg x d ultralente insulin
Study: 20881844
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 12 mg/day
Study: 20881844
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER 18 mg/day
Study: 19376787
Drug: Rocuronium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1.0 mg kg(‐1)
Study: 15151527
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (4 mg day(‐1))
Study: 10886043
Drug: Anti-Helicobacter therapy
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Helicobacter therapy in controls (D)
Study: 1531719
Drug: Low-dose, intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, intradermal hepatitis B vaccination (2 micrograms)
Study: 1531719
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of 2 micrograms i.d.
Study: 1531719
Drug: Low-dose, intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, intradermal hepatitis B vaccination (3 doses at 0, 1, and 6 months)
Study: 1531719
Drug: Low-dose, intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, intradermal hepatitis B vaccination (2 doses)
Study: 1531719
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of 2 micrograms i.d. at month 25
Study: 6357209
Drug: suprofen 200
Normalized name: suprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: suprofen 200 mg
Study: 3893444
Drug: pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentazocine 30 mg
Study: 26996595
Drug: HDR (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDR (7 Gy each in three fractions, repeated weekly)
Study: 26996595
Drug: PDR (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR (70 cGy hourly pulses for 39 hours, total 27 Gy)
Study: 23732307
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of laninamivir octanoate once daily for 2 days (LO-2)
Study: 23732307
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of laninamivir octanoate once daily for 3 days (LO-3)
Study: 12862326
Drug: Acute caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute caffeine consumption (5 mg x kg(‐1) body mass)
Study: 12862326
Drug: Chronic caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic caffeine consumption (5 mg x kg(‐1) body mass for 7 days)
Study: 27771748
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral d-amphetamine
Study: 31340232
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg oral midazolam (first session)
Study: 31340232
Drug: oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo (first session)
Study: 27926633
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy
Study: 27926633
Drug: Calcium+Vitamin D
Normalized name: Calcium/Cholecalciferol 500 MG-10 MCG Oral Tablet [LEADER CALCIUM+VITAMIN D3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium+Vitamin D + Hormone Therapy
Study: 19556262
Drug: Prednisone 1
Normalized name: prednisone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1 mg kg(‐1) day(‐1) for 4 weeks followed by 0.33 mg kg(‐1) day(‐1) for 5 months and azathioprine 2 mg kg(‐1) day(‐1) for 6 months (Group 1)
Study: 17541639
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine co-administered with DTPa-HBV-IPV/Hib vaccine
Study: 17541639
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine alone
Study: 17541639
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of DTPa-HBV-IPV/Hib vaccine
Study: 23142309
Drug: Pelargonium sidoides
Normalized name: PELARGONIUM SIDOIDES ROOT
DrugBank: Pelargonium sidoides root (DB16583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelargonium sidoides daily for 5 days (n=30)
Study: 23142309
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, n=31)
Study: 16713009
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg/day for 12 weeks
Study: 16713009
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not administered valsartan)
Study: 14716700
Drug: Galantamine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (up to 12 mg twice daily)
Study: 9252210
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (mean intake 19.8 g day(-1))
Study: 3325229
Drug: Isosorbide-5-mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (20 mg) - Group M2 (2 tablets per day)
Study: 3325229
Drug: Isosorbide-5-mononitrate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (20 mg) - Group M3 (3 tablets per day)
Study: 3325229
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate retard (40 mg) - Group D2 (2 tablets per day)
Study: 3325229
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate retard (40 mg) - Group D3 (3 tablets per day)
Study: 3325229
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate retard (40 mg)
Study: 20220063
Drug: Imatinib high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib high dose or 400 mg + interferon-alpha
Study: 15562383
Drug: Transdermal estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogens (micronized 17beta‐estradiol; Systen, Janssen‐Cilag, Switzerland) and progesterone
Study: 15562383
Drug: Oral hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormones (Cyclo‐Menorette)
Study: 10359391
Drug: Androstenedione 300
Normalized name: androstenedione
DrugBank: Androstenedione (DB01536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androstenedione 300 mg/d (n = 10)
Study: 7727473
Drug: Ganciclovir (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (5 mg/kg intravenously) given three times weekly for the first 6 weeks after transplantation and for another 2 weeks for each treated rejection episode between 6 and 12 weeks.
Study: 7727473
Drug: Ganciclovir (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganciclovir (10 mg/kg/day for 2 weeks)
Study: 24899662
Drug: Allopurinol treatment
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol treatment (10 patients treated for 4 weeks)
Study: 8777826
Drug: Losartan potassium,
Normalized name: Losartan Potassium, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan potassium, 50 mg orally
Study: 8777826
Drug: Enalapril, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 20 mg orally
Study: 8777826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of losartan and enalapril
Study: 6094451
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g cefotaxime before surgery
Study: 6094451
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g cefoxitin pre-operatively and every 8 h for no more than 24 h post-operatively
Study: 27038786
Drug: i-Sleep (5-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-Sleep (5-session guided online treatment)
Study: 20345617
Drug: Intravenous prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prostaglandin E1 (PGE) 60 microg in 100 mL saline
Study: 15991504
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) ketamine 0.15 mg kg(‐1) before induction and 2 microg kg(‐1) min(‐1) during anaesthesia
Study: 12762609
Drug: 5% Eutectic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 3 minutes
Study: 12762609
Drug: 5% Eutectic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 5 minutes
Study: 12762609
Drug: 5% Eutectic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Eutectic Mixture of Local Anesthetics (EMLA) cream applied for 10 minutes
Study: 10477166
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg i.m. daily (plus placebo)
Study: 10477166
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg i.m. daily plus dexamethasone 8 and 4 mg twice daily
Study: 6387892
Drug: Cephalexin (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (25-50 mg/kg body weight per day for 3 days)
Study: 6387892
Drug: Nitrofurantoin (3-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (3-4 mg/kg/day for 10 days)
Study: 31808408
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (Group 2) - Two pre-RP physical therapist-guided PFMT sessions, including exercises and electromyographic biofeedback, and verbal and written instructions to continue PFMT until RP, which was then resumed after urethral catheter removal.
Study: 22174437
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg) administered alone on day 4
Study: 22174437
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg) administered with darunavir/ritonavir (600/100 mg) on days 15-18
Study: 7921798
Drug: 19% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19% hydrogen peroxide solution
Study: 7921798
Drug: 35% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35% hydrogen peroxide solution
Study: 3713101
Drug: i.v. immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. immunoglobulin (4 X 100 ml) combined with antibiotics
Study: 3713101
Drug: antibiotics alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotics alone
Study: 30968258
Drug: Cefotaxime 100–150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 100–150 mg/kg/day
Study: 28523596
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg daily